{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-24-000017","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.173465+00:00","generated_at":"2026-06-05T23:15:33.813586+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbCellera FY2023 revenue $38M (down 92% YoY), net loss $0.51/share","bullets":["Revenue fell to $38.0M from $485.4M in FY2022; research fees were $35.6M.","Net loss of $146.4M ($0.51 basic & diluted EPS) vs net income of $158.5M in 2022.","R&D expenses surged to $175.7M (up 63% YoY) on program and platform investments.","Cumulative partner-initiated program starts reached 87; 13 molecules in clinic.","Advanced two internal programs (ABCL635, ABCL575) into IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-24-000017","json":"https://secwatch.observer/filing/0001703057-24-000017.json","markdown":"https://secwatch.observer/filing/0001703057-24-000017.md","text":"https://secwatch.observer/filing/0001703057-24-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/0001703057-24-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/abcl-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:15:33.813586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be168079e4c8915aa451cca7e05a387e6fac4dcb","claim":"AbCellera Biologics Inc. reported full year 2023 results: revenue $38.0 million, net income $146.4 million, or $(0.51) per share on a basic and diluted basis, EPS $(0.51) per share on a basic and diluted basis.","evidence_excerpt":"the press release is furnished herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- NEWS RELEASE AbCellera Reports Full Year 2023 Business Results 2/20/2024 ● Total revenue of $38 million, compared to $485 million in FY 2022 ● Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year ● Net loss of $0.51 per share on a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/0001703057-24-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$38.0 million"},{"label":"Net income","value":"$146.4 million, or $(0.51) per share on a basic and diluted basis"},{"label":"EPS","value":"$(0.51) per share on a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}